Page 32 - Memoria FEHH - SEHH 2017
P. 32

 MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Hernández- Sánchez JM, Quijada-Álamo M, Sánchez-Pina JM, Sala-Valdés M, Araújo-Silva F, Kohlmann A, Fuster JL, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer. 2017 Jul 11;117(2):256-65.
• Martínez-Laperche C, Kwon M, Franco-Villegas AC, Chillón MC, Castro N, Anguita E, Dolz S, Rodríguez-Medina C, Hermosín L, Bellón JM, Prieto-Conde MI, Barragán E, Gómez-Casares M, Ayala R, Martínez-López J, González-Díaz M, Díez-Martín JL, Buño I; Cooperative Group for Molecular Biology in Haematology (GBMH). Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. Br J Haematol. 2018 May;181(4):542-6.
• Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Es- teve J, Feliu E, Solé F, Orfao A, Ribera JM. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018 Jul 24;11(1):96.
• Hernández-Boluda JC, Pereira A, Correa JG, Álvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Vélez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gó- mez-Casares MT, Mata-Vázquez MI, Mora E, Gómez M, Cervantes F. Prognostic risk models for transplant decision- making in myelofibrosis. Ann Hematol. 2018 May;97(5):813-20.
• Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abáigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J. Mutations in the DNA methylation pathway and number of driver mutations predictresponse to azacitidine in myelodysplastic syndromes. Oncotarget. 2017 Oct 27;8(63):106948- 61.
• Hernández-Boluda JC, Pereira A, Correa JG, Álvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez- Encinas M, Estrada N, Vélez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2018 Feb;32(2):553-5.
 GRUPO DE BIOLOGÍA MOLECULAR EN HEMATOLOGÍA (GBMH)
32
 























































































   30   31   32   33   34